Research Analysts Set Expectations for XBIO FY2025 Earnings

Xenetic Biosciences Inc (NASDAQ:XBIO) – Research analysts at HC Wainwright cut their FY2025 earnings estimates for shares of Xenetic Biosciences in a note issued to investors on Thursday, March 20th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($3.24) per share for the year, down from their previous estimate of ($0.66). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ FY2026 earnings at ($0.45) EPS, FY2027 earnings at ($0.54) EPS and FY2028 earnings at ($0.48) EPS.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.48). The firm had revenue of $0.65 million for the quarter, compared to analysts’ expectations of $0.18 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%.

Xenetic Biosciences Price Performance

Shares of NASDAQ:XBIO opened at $3.37 on Monday. The company’s fifty day moving average price is $3.98 and its 200 day moving average price is $3.99. Xenetic Biosciences has a 12 month low of $2.78 and a 12 month high of $5.20. The firm has a market capitalization of $5.20 million, a P/E ratio of -1.27 and a beta of 2.17.

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC increased its stake in shares of Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,550 shares of the company’s stock after acquiring an additional 9,700 shares during the quarter. Renaissance Technologies LLC owned about 1.66% of Xenetic Biosciences worth $102,000 at the end of the most recent quarter. Institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.